In a patent infringement litigation between rival manufacturers of dermal fillers, CRA was asked to opine on damages suffered by plaintiffs. In an expert report, CRA analyzed lost profits and reasonable royalty damages, examining the market and buying patterns for dermal fillers. In considering the hypothetical negotiation, CRA examined features linked to the patents at issue and other features not subject to the negotiation.
Pharmaceuticals and Biotechnology Litigation
In this Jan-Mar 2023 issue of Corporate Disputes e-magazine, Sean Sheridan, along with other industry professionals, discusses significant developments shaping...